Polyclonal Antibody to Fibroblast Growth Factor 1, Acidic (FGF1)
| Code | Size | Price |
|---|
| PAA032Ov01-20ul | 20ul | £95.00 |
Quantity:
| PAA032Ov01-100ul | 100ul | £182.00 |
Quantity:
| PAA032Ov01-200ul | 200ul | £247.00 |
Quantity:
| PAA032Ov01-1ml | 1ml | £571.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Sheep
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
ECGF; AFGF; ECGFA; ECGFB; FGF-Alpha; FGFA; HBGF1; ECGFB; HBGF1; Acidic Fibroblast Growth Factor; heparin-binding growth factor 1; Endothelial Cell Growth Factor, Beta
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Fibroblast Growth Factor 1, Acidic
Reactivity:
Cp;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Fibroblast Growth Factor 1, Acidic (FGF1) | RPA032Ov01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||